JAK2 and myeloproliferative disorder: The two genetic alterations may be identified either simultaneously or JAK2 mutation may be found in the setting of a previously diagnosed CML treated with a tyrosine kinase inhibitor (TKI) or finally BCR::ABL1 translocation may develop in patients with a long history of JAK2-positive MPN.